source
- Kyverna reports year-long efficacy and clean safety for miv-cel CAR-T in autoimmune trialsKyverna Therapeutics released one-year data for its CAR-T candidate miv-cel in stiff person syndrome and 18-month data in generalized myasthenia gravis. The single dose showed durable clinical ben…
- Flagship Pioneering secures Pentagon contract to develop biological threat countermeasuresFlagship Pioneering, a biotech investment firm, has been awarded a contract by the U.S. Department of Defense. The contract aims to advance technologies that can serve as countermeasures against b…